Ocugen, Inc. (OCGN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$32.2M
Cash & Equivalents
$21.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$498M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-28 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05956626 | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | PHASE3 | Active Not Recruiting | 51 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.